A New York Times report details how the FDA recently sent a letter to a division of Pfizer regarding the company’s failure to properly investigate the safety of its EpiPens, which it manufactures for Mylan, based on adverse event reports filed by consumers. The pens are used by patients to deliver epinephrine during potentially life-threatening allergic reactions.
Complaints centered on a malfunctioning mechanism within the EpiPens. The ...
continue reading...